01Purpose and principlesWhat the treatment does and how it fits into care.
An implant reconstructs volume beneath a surgically created tissue envelope. The result depends on both the device and the living tissues surrounding it: skin thickness and blood supply, muscle or other cover, scars, radiation exposure and the opposite breast all matter. Implant reconstruction can avoid a distant flap donor site and may reduce the initial operative burden, but introduces a permanent device and the possibility of further procedures. Explain differences in softness, movement, sensation, rippling and the contour when clothed or undressed. An apparently simple initial operation can still create a prolonged reconstructive journey.
Direct-to-implant and expander-based reconstruction are options for selected circumstances, not competing labels with one universal winner. A definitive implant may be appropriate when the envelope and desired volume permit safe placement. An expander can allow gradual adjustment when that endpoint should not be attempted immediately. Some operations also use acellular dermal matrix or other support, with associated seroma and infection considerations. The surgeon must explain the material, purpose, risks and alternatives. Patient preference about donor-site surgery, repeat visits and future device procedures contributes to choosing the whole pathway.
Key points
- Implant reconstruction requires adequate, viable soft-tissue cover. A direct-to-implant operation places the intended implant at mastectomy; an expander pathway creates or adjusts the envelope in stages before the definitive result is established.
- Prepectoral implants lie above pectoralis major; subpectoral approaches use muscle cover. Acellular dermal matrices or other support may assist selected techniques, but they do not supply a new blood circulation to ischaemic mastectomy skin.
- Increasing pain, spreading erythema, wound separation, threatened skin or an exposed implant requires prompt surgical assessment. Systemic illness demands emergency care; changing expansion volume or giving reassurance cannot replace assessment of infection and tissue viability.
- Radiotherapy may increase reconstructive complications and capsular contracture. Discuss technique and staging with breast, plastic and oncology teams, including delayed autologous alternatives, while keeping the cancer indication for radiotherapy separate.
- Implants are not lifetime devices, but an asymptomatic implant does not need replacement merely because a fixed number of years has passed. Explain possible future revision, preserve device details and investigate new symptoms according to their cause.
- Current MHRA advice does not recommend routine removal solely for an asymptomatic textured implant. Late swelling or a mass needs assessment for BIA-ALCL and other causes; systemic symptom reports deserve a respectful assessment without asserting an established causal disease or guaranteed cure after explantation.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Assess the available skin and its perfusion, scars and previous radiotherapy. A tight closure, increasing skin tension or questionable viability may alter the planned implant volume, cover or timing. A matrix can support an implant but cannot make non-viable skin reliable. The intraoperative tissue assessment can therefore change an apparently agreed direct-to-implant plan.
Prepectoral placement avoids positioning the implant beneath the pectoralis muscle; subpectoral reconstruction uses muscle cover but may produce movement or distortion with muscle contraction. Thin cover can make rippling or implant edges more apparent. Discuss these features together rather than equating the absence of muscle dissection with absence of complications.
Review pain, redness, warmth, swelling, wound discharge, separation and skin discolouration with observations and the person's general condition. These findings can reflect infection, a collection, bleeding or threatened tissue. Early contact with the operating service is important because worsening cover can endanger the implant as well as the overlying skin.
Increasing firmness and painful distortion can suggest capsular contracture, while volume or contour change may raise an integrity question. A new late swelling, fluid collection or mass also requires assessment for implant-associated malignancy. Do not assume that the age of an implant, its texture or a prior benign problem explains every new symptom.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Preoperative breast and tissue assessmentFirst step - Why
- Match the proposed implant volume and cover to skin quality, mastectomy requirements and the patient's goals.
- Interpretation and limitations
- Review imaging and cancer extent for the actual oncological operation, then document the reconstructive examination. The final envelope assessment may only be possible during surgery. Agree in advance which alternative sequence the patient would accept if direct implantation proves unsuitable, so that a predictable technical uncertainty does not become an unconsented change.
- 02
Oncology and radiotherapy plan review - Why
- Identify anticipated treatment effects that may alter the implant technique, stages and complication discussion.
- Interpretation and limitations
- Distinguish confirmed radiotherapy requirements from a decision awaiting pathology. NICE permits discussion of immediate reconstruction in either situation, but warns that implants may be more affected than flaps. Neither inserting a temporary device nor delaying exchange guarantees avoidance of radiation-related complications; specify the intended sequence and review point.
- 03
Assessment of a symptomatic reconstruction - Why
- Determine whether pain, swelling or skin changes indicate infection, bleeding, cover failure, an integrity problem or another diagnosis.
- Interpretation and limitations
- Start with examination and systemic assessment, escalating urgently when the patient is unwell or skin is threatened. Select imaging, microbiology or fluid/tissue investigation through the implant and breast team for the suspected problem. A late seroma or mass must not be labelled ordinary implant wear before the appropriate malignancy assessment.
- 04
Implant and operative records - Why
- Identify the device, prior procedures and tissue planes needed for safe follow-up, revision or investigation of a product concern.
- Interpretation and limitations
- Retain the manufacturer, model, fill, surface, size and device identifiers with the operation date and subsequent exchanges. Give the patient accessible information about the implant. Records support recall and symptom assessment, but a manufacturer name alone cannot establish an individual's malignancy risk because previous implant exposures and other factors may be relevant.
04Treatment approachPreparation, options, escalation and aftercare.
01Case: staged implant reconstructionBuild a safe envelope before the final volumeFirst stepA patient chooses implant reconstruction, but the surgeon considers the desired final volume unsuitable for immediate placement within the available, viable mastectomy envelope.+
- 1Before surgery, she compares an expander pathway with a smaller immediate result and autologous alternatives. She prefers to avoid a distant donor site and accepts repeat visits and possible exchange surgery. The team documents the permitted change in technique if the skin assessment is less favourable than expected.
- 2The mastectomy skin is assessed as viable, and an expander is placed at a volume appropriate to the tissues in this illustrative operation. The wound is closed without attempting the full desired breast volume. The patient receives clear contact instructions for worsening pain, swelling, redness or skin breakdown.
- 3At review the incision has healed, there is no collection or infection and the skin remains satisfactory. The surgeon begins the agreed expansion process, checking comfort and skin tension at each visit rather than following a universal filling volume or automatic calendar schedule.
- 4DefinitiveThe patient reaches a volume that meets the agreed goal without a threatened wound. The team reviews the final oncology plan and discusses the definitive implant stage, device characteristics and revision risks. Her recorded outcome is a healed, tolerated expansion with an agreed next operation, rather than a promise that no further procedures will be needed.
02Case: threatened implant coverRespond to a changing wound before continuing expansionTen days after reconstruction, a patient reports increasing pain and a darkening area beside a separating mastectomy incision.+
- 1The clinician contacts the reconstructive team promptly and assesses general condition, observations, wound extent and any implant exposure or collection. Systemic deterioration would trigger emergency assessment. The next expansion appointment is not used as the response to a potentially failing skin envelope.
- 2At surgical review the threatened tissue is confirmed and the team reassesses whether the current implant plan can be preserved. The patient hears the options for treating the non-viable tissue and protecting or revising the reconstruction, including the possibility of removing a device when safe cover cannot be maintained.
- 3In this example the surgeon excises the non-viable skin and removes the device because safe viable tissue cover cannot be maintained. Subsequent examination shows healthy wound edges and no progressing skin loss. The patient receives a revised reconstructive sequence and understands why the original expansion schedule has stopped.
- 4The breast and oncology teams review the wound outcome against the adjuvant-treatment timetable. Follow-up records the tissue findings, procedures and the person's priorities. Successful early wound management does not establish that the original implant result will ultimately be retained.
03Case: new late swellingInvestigate a symptom before recommending device surgerySix years after an implant reconstruction, a patient develops progressive unilateral swelling without an obvious wound infection and asks for both implants to be removed immediately.+
- 1The clinician recognises that late swelling needs an implant-specific assessment and arranges prompt review through the breast or reconstructive service. The history covers the onset, pain, trauma, previous devices and operations; examination looks for fluid, a mass, skin change and regional nodes.
- 2The consultation explains common causes alongside BIA-ALCL and other uncommon capsule malignancies. The service reviews the device record and arranges investigation of the clinical finding. The cancer possibility is neither dismissed because she feels well nor presented as a diagnosis before the required assessment.
- 3At specialist review the swelling is confirmed and an investigation plan with named follow-up responsibility is completed. She understands why diagnostic information is needed to select the extent and timing of surgery. Her preference for removal remains part of the discussion, but it does not replace establishing what is being treated.
- 4She is given instructions to seek earlier assessment for rapid enlargement, severe pain, redness or systemic illness. The documented endpoint is a completed specialist assessment and investigation arrangement; the eventual diagnosis and operative plan will be reviewed with her once the results are available.
05Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Check skin viability, wound closure, collections, pain and infection at early follow-up and before expansion. Record why a filling or exchange stage is proceeding or being changed. A wound concern should have a prompt clinical response, not merely a later appointment.
- Reconcile pathology and radiotherapy planning with the reconstructive stages. Review tissue condition after cancer treatment and explain any change to exchange, revision or an autologous alternative. Document the person's decision after learning how the revised sequence affects recovery and risk.
- Ask about firmness, contour, movement, discomfort and the impact on everyday life at longer follow-up. Investigate a new lump, late swelling or loss of volume rather than attributing it to expected ageing without assessment. Preserve records of each device change.
- For reported systemic symptoms, take a clinical history, assess other potential causes and explain what is known and uncertain about the association with implants. Discuss benefits and harms of any proposed removal individually; do not promise symptom resolution or imply that the symptoms are unimportant.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Scar capsule and contracture differ
A fibrous capsule is the body's response around an implant. Contracture describes a clinically important tightening that may produce firmness, distortion or pain. Explain that recognising a capsule does not by itself establish a need for surgery; severity, symptoms and alternative diagnoses determine the assessment and options.
Texture informs honest counselling
MHRA reports a greater BIA-ALCL association with macrotextured surfaces, but brand comparisons and personal risk estimates are complicated by device histories and reporting denominators. Use current regulator advice without converting sales-based reporting rates into the probability for an individual patient.
Rare capsule cancers are distinct
SCC and other lymphomas have been reported in implant capsules and are distinct from BIA-ALCL. MHRA notes insufficient evidence to identify comparative risks across populations or manufacturers. Explain the potential risks and the need to assess new changes; current evidence does not establish a causal mechanism or justify a routine preventive operation.
Removal is also an operation
For someone without symptoms or findings, routine textured-implant removal is not the MHRA recommendation. The extent of capsule surgery needs an indication: complete removal can have complications and its ability to prevent future BIA-ALCL is uncertain. Discuss a person's concerns without presenting en-bloc surgery as a harmless default.
07Common pitfallsFrequent interpretation and management errors.
- 01
Assuming a matrix corrects poor skin perfusion. Structural support and vascular supply are different requirements; a threatened envelope needs the operating team's reassessment of cover, volume and timing.
- 02
Promising routine replacement at ten years or lifelong freedom from revision. Device age informs the history, while symptoms, findings, current product advice and individual goals guide decisions.
- 03
Calling every postoperative red breast a benign reaction to reconstruction material. Examine the wound and systemic condition and assess infection, fluid and skin viability before choosing observation.
- 04
Treating uncertainty about systemic symptoms as proof either of a single implant-caused disease or of no possible relationship. Evaluate the symptoms and discuss the limits of evidence and surgery honestly.